Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

This study has been completed.
Information provided by (Responsible Party):
PD Dr. Jochen G. Mainz, University of Jena Identifier:
First received: March 12, 2010
Last updated: November 28, 2014
Last verified: November 2014

Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.

Condition Intervention
Cystic Fibrosis
Drug: sodium chloride 6%
Drug: sodium chloride 0,9%

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial

Resource links provided by NLM:

Further study details as provided by University of Jena:

Primary Outcome Measures:
  • Changes in the Sino-nasal-outcome test SNOT-20 adapt CF [ Time Frame: days 1, 29, 57 and 85 ]

Secondary Outcome Measures:
  • Changes in the nasal lavage fluid and in the serological markers of inflammation [ Time Frame: days 1, 29, 57 and 85 ]

Enrollment: 69
Study Start Date: March 2010
Study Completion Date: June 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: sodium chloride 6%
Cross-Over! "experimental" (days 1 - 28), then Wash-Out (28 days),then "placebo comparator" (days 57 - 85).
Drug: sodium chloride 6%
  • one ampoule sodium chloride 6% per day
  • inhalation use
  • for 28 days
Placebo Comparator: sodium chloride 0,9%
Cross-Over! "placebo comparator" (days 1 - 28), then Wash-Out (28 days),then "experimental" (days 57 - 85).
Drug: sodium chloride 0,9%
  • one ampoule sodium chloride 0,9% per day
  • inhalation use
  • for 28 days


Ages Eligible for Study:   8 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has a confirmed diagnosis of cystic fibrosis based on: 2 positive sweat chloride tests and/or genetic characterization
  • Subject is 8 years of age or older
  • informed consent of the patient or legal representative
  • Women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol (failure rate <1% e.g. implants, combined oral contraceptives, injectables, some intrauterine devices, sexual abstinence or vasectomised partner)

Exclusion Criteria:

  • Subject has no chronic rhinosinusitis (European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS-criteria)
  • Subject has a critical condition defined as: forced expiratory volume at one second < 30% and / or arterial oxygen saturation < 93% without O2-substitution; need of O2-substitution
  • Subject had an ENT surgery within 6 months prior to study
  • Subject participates in another clinical trial within 30 days prior to study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01086839

Zentrum für Kinder- und Jugendmedizin
Heidelberg, Baden Würtemberg, Germany, 69120
Tübingen, Baden-Württemberg, Germany
Medizinische Klinik Innenstadt
München, Bayern, Germany, 80336
Universitätsklinikum Würzburg
Würzburg, Bayern, Germany, 97080
Zentrum für Kinder- und Jugendmedizin
Greifswald, Brandenburg, Germany, 17487
J.W. Goethe Universität - Abtl. Pneumologie
Frankfurt, Hessen, Germany, 60590
Klinik für Kinder- und Jugendmedizin
Münster, Nordrhein-Westfalen, Germany, 48149
Leipzig, Sachsen, Germany, 04103
Mukoviszidosezentrum der Friedrich-Schiller-Universität
Jena, Thüringen, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany, 13353
Hamburg, Germany
Sponsors and Collaborators
University of Jena
Study Chair: Jochen Mainz, M.D. University of Jena
  More Information

Responsible Party: PD Dr. Jochen G. Mainz, PD Dr., University of Jena Identifier: NCT01086839     History of Changes
Other Study ID Numbers: NaCl 6.0%-nasal-CF
Study First Received: March 12, 2010
Last Updated: November 28, 2014

Keywords provided by University of Jena:
Cystic Fibrosis
chronic rhinosinusitis

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases processed this record on May 25, 2017